neuroendocrine%20tumors
NEUROENDOCRINE TUMORS
Neuroendocrine tumors are rare, small, slow-growing epithelial neoplasms with predominant neuroendocrine differentiation found in most organs of the body.
They arise from cells throughout the diffuse endocrine system.
Carcinoid tumors and pancreatic neuroendocrine tumors are the most common.
Carcinoid tumors arise from the lungs & bronchi, stomach, small intestine, appendix, rectum or thymus.
Majority of the neuroendocrine tumors are sporadic but some tumors are caused by inherited genetic syndromes such as multiple endocrine neoplasia, Von-Hippel Lindau disease, tuberous sclerosis complex and neurofibromatosis.
They have the ability to store and secrete various peptides and neuroamines.

Surgical Intervention

  • Surgical management should be individualized w/ the ultimate therapeutic decisions & approaches decided after a full multidisciplinary evaluation
  • Surgery can be curative or palliative
  • It can be primary tumor resection or tumor debulking
  • It has curative potential & can improve survival
    • It can lessen or remove the risk of progressive symptoms such as bowel obstruction
  • Early intervention can also increase the chance of successful surgery & decrease technical complications
  • Definitive resection of the primary tumor should always be performed whenever technically feasible
    • It is the primary treatment approach for most localized carcinoid tumors & pancreatic NETs
    • Primary tumor removal by segmental resection & lymphadenectomy are recommended
  • Prophylactic cholecystectomy is also advised in patients undergoing surgery for NETs of the digestive tract in order to mitigate biliary toxicity of somatostatin analogs & prevent chemical cholecystitis if transcatheter arterial chemoembolization is done
  • Ensure that Octreotide is given preoperatively & intraoperatively to avoid intraoperative carcinoid crisis in patients w/ functional tumors
  • Trivalent vaccine (eg H influenzae b, meningococcal group C, pneumococcus) should be given preoperatively to patients who will require splenectomy
Curative Surgery
  • Resection of the primary tumor should be accompanied by a thorough intraoperative evaluation for synchronous tumors or metastatic disease
    • Resectable liver metastasis should be removed
    • Selective portal vein embolization is considered in patients w/ borderline liver reserve in order to induce liver hypertrophy
    • Liver transplantation is an option in young patients <50 yearr old if:
      • Primary tumor originates from the gastrointestinal tract
      • Tumor is drained by the venous portal system
      • Disease progression is controlled for at least 6 months before transplantation
Palliative Surgery
  • Cytoreductive surgery is recommended in patients when complete resection of the tumor is not possible
  • Consists of combination of multiple techniques such as hepatectomy, local ablative therapies (eg radiofrequency ablation, cryotherapy, or microwave therapy), intra-abdominal organ resection, & bypass procedures
  • Aims to stabilize or improve symptoms & decrease or normalize hormone levels
  • Can reduce tumor bulk, prevent or delay complications from local or distant disease, decrease hormone levels, & prolong survival
  • Requires the assessment by a multidisciplinary team to ensure care & provide case-specific palliative options
  • Hepatic arterial embolization w/ or w/o chemotherapy is another cytoreductive option for patients who are not surgical candidates
  • Radioembolization for unresectable metastatic liver NETs may also be effective
Localized NETs
Appendix
  • Most appendiceal carcinoids are found after appendectomy & majority are located at the tip of the appendix
  • Careful pathological investigation of the specimen is required
  • Completely excised, small, well-differentiated carcinoid measuring ≥1 cm & confined to the tip of the appendix can be considered as cured if there is no evidence of lymphovascular invasion or invasion into the mesoappendix
  • Simple appendectomy is sufficient for low-grade appendiceal NETs <2 cm confined to the appendix
  • Right hemicolectomy is recommended in the following conditions:
    • Appendiceal carcinoids w/ evidence of tumor invasion at the base of the appendix
    • Tumors >2 cm
    • Undetermined tumor size
    • Incompletely resected tumors
    • Tumors w/ lymphovascular invasion
    • Tumors w/ invasion of the mesoappendix
    • Intermediate to high-grade tumors
    • Mixed histology (eg goblet cell carcinoid, adenocarcinoid)
  • Obvious mesenteric nodal involvement
Cecum
  • Carcinoids of cecum are frequently metastatic at the time of diagnosis
  • Usually present as silent, large, bulky tumors manifesting w/ gastrointestinal hemorrhage or obstruction
  • More aggressive than appendiceal carcinoid
  • Surgical excision w/ adequate resection of mesenteric lymph-node bearing tissue is recommended
  • Careful pathological examination is required especially in small lesions
Duodenum
  • If feasible, endoscopic resection is recommended & if performed, follow-up EGD as indicated
  • For nonmetastatic duodenal carcinoid tumors other options include:
    • Transduodenal local excision w/ or w/o lymph node sampling
    • Pancreatoduodenectomy
Jejunum/Ileum/Colon
  • Bowel resection w/ regional lymphadenopathy may be considered
    • Intra-operative assessment of the superior mesenteric artery & vein is also recommended
Pancreas
  • Local resection or enucleation of pancreatic NETs is recommended whenever feasible
    • More advanced surgical resections such as Whipple resections are not routinely performed & should only be done in carefully selected patients
  • Pancreatic NETs, except for insulinomas, are surgically managed by a laparotomy to allow an extensive exploration of the abdomen & look for lymph node metastases
  • All insulinomas regardless of size should undergo resection due to hypoglycemic complications
  • Intrapancreatic single tumors if localized preoperatively can be cured in almost all cases using laparoscopic approach
    • Surgical cure rates are high for insulinomas & for sporadic gastrinomas
    • Cure rates of other pancreatic NETs are lower because they are diagnosed during advanced disease state
Rectum
  • It is recommended to have endoscopic or transanal excision in tumors ≥2 cm
  • Low anterior resection or abdominoperineal resection is recommended for tumors >2 cm w/ tumor invasion of the muscularis propria or tumors associated w/ lymph node metastases
Stomach
  • Endoscopic removal w/ biopsy & subsequent follow-up is recommended for tumors <2 cm
    • Wedge resection may also be used for patients w/ tumors <2 cm & w/ normal gastrin levels
  • Local surgical resection is done for tumors >2 cm w/ recurrent tumors or w/ >6 polyps
  • Radical gastric resection w/ lymphadenectomy is recommended for patients w/ solitary or multiple tumors >2 cm in size & w/ normal gastrin levels
  • Antrectomy may be performed in patients w/ type 1 gastric NETs & chronic atrophic gastritis to eliminate the source of gastric production
  • Partial gastrectomy & lymph node dissection are required for type 3 isolated sporadic gastric NETs considered only in selected patients
    • Clinical benefit is not clearly established in patients w/ asymptomatic small-volume disease & may not be applicable in patients w/ large-volume liver metastatic disease
Thymus
  • Generally treated w/ surgical resection w/o adjuvant therapy
Metastatic NETs
Pancreas
  • Pancreatic NETs have highly variable growth patterns
    • Almost all of insulinomas are benign while more than half of other symptomatic pancreatic NETs & nonfunctional pancreatic NETs have hepatic metastasis
    • High 5-year survival rates are noted in patients w/ resected pancreatic NETs, w/ incomplete resections & w/ diffuse hepatic disease
  • Surgical resection of all visible tumor is only feasible in a few number of patients w/ pancreatic NETs w/ liver metastasis
    • Studies showed no evidence of symptom control or prolonged survival
    • Despite this, surgical resection should still be attempted because of the low efficacies of other tumor treatments
  • Hepatic arterial embolization is also recommended in patients w/ pancreatic NETs w/ hepatic metastasis who are not surgical candidates, disease limited to the liver w/ patent portal vein, & preserved functional status
    • Similar response rates of more than half is also observed w/ gastric & carcinoid tumors
    • Especially considered in patients w/ functional pancreatic NETs in which hormone excess state cannot be controlled by other treatment modalities
  • Radiofrequency ablation & cryoablation, w/ or w/o cytoreductive surgery, via percutaneous or laparoscopic approach are considered in selected patients w/ advanced pancreatic NETs
Stomach
  • Hepatic resection provides long-term symptomatic relief & prolongs survival in patients w/ hepatic metastasis localized to one lobe
  • Orthotopic liver transplantation is only attempted in a small number of patients
    • There is a 5-year survival rate if there are poor prognostic factors such as prior extensive upper abdominal surgery, neuroendocrine primary tumor in the duodenum or pancreas, & hepatomegaly
    • There is an increased 5-year survival rate in the absence of risk factors
    • Thus, liver transplantation cannot be routinely performed in patients w/ liver-isolated metastatic NETs but it can be an option for some young patients w/o risk factors
  • Hepatic arterial embolization is recommended as a palliative option in patients w/ liver metastasis who cannot undergo surgical resection but have preserved performance status, disease confined to the liver w/ patent portal vein
    • Considered in patients w/ functional carcinoid tumors in which hormone excess cannot be controlled by other methods
    • Response rates are decreased hormonal secretion or radiographic regression by half
    • Techniques used are bland embolization, chemoembolization, embolization w/ chemotherapy beads, & embolization using radioisotopes
  • Radiofrequency ablation & cryoablation, used alone or in combination w/ surgical debulking, should be considered only in selected patients
    • Clinical benefit is not clearly established in patients w/ asymptomatic small-volume disease & may not be applicable in patients w/ large-volume liver metastatic disease
Functional Pancreatic NETs
Gastrinomas
  • Exploratory surgery including duodenotomy & intraoperative ultrasound w/ enucleation or local resection of tumors & removal of periduodenal nodes is recommended
  • Pancreatoduodenectomy is recommended for invasive/deep gastrinomas located w/in the head of the pancreas or proximal to the main pancreatic duct
  • Distal pancreatectomy w/ or w/o splenectomy may be considered for distal tumors
Insulinomas
  • Enucleation is the primary treatment for exophytic or peripheral insulinomas as they are primarily benign
  • If enucleation is not possible, options include:
    • Pancreatoduodenectomy for tumors in the head of the pancreas
    • Distal pancreatectomy w/ preservation of the spleen for small tumors not involving the splenic vessels
Glucagonomas
  • Mostly malignant, calcified & located in the tail of the pancreas
  • Distal pancreatectomy w/ resection of the peripancreatic lymph nodes & splenectomy is recommended
    • Enucleation or local excision w/ peripancreatic lymph nodes resection may be considered for peripheral tumors <2 cm
  • Perioperative anticoagulation should be considered due to increased risk of pulmonary emboli
VIPomas
  • Distal pancreatectomy w/ resection of the peripancreatic lymph nodes & splenectomy is recommended
  • Pancreatoduodenectomy w/ peripancreatic lymph nodes dissection is suggested for tumors w/in the head
Nonfunctional Pancreatic NETs
  • Surgical resection is recommended except in:
    • Patients w/ other life-limiting comorbidities
    • High surgical risk
    • Widely metastatic disease
  • For locoregional tumors <2 cm in size, enucleation, distal pancreatectomy, or pancreatoduodenectomy w/ or w/o regional lymph node removal may be considered
  • Resection (pancreatoduodenectomy, distal pancreatectomy) w/ total removal of the tumor w/ negative margins (including adjacent organs) & regional lymph nodes is recommended in tumors >2 cm in size or malignant-appearing functional & nonfunctional pancreatic NETs
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Gastroenterology - Malaysia digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Elvira Manzano, 6 days ago
Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.
Yesterday
Drinking coffee, whether caffeinated or decaffeinated, is associated with a reduced risk of cardiovascular disease (CVD) and ischaemic heart disease (IHD) mortality in patients with a prior myocardial infarction (MI), according to a recent study.
3 days ago
Breast cancer patients have notably different microbiomes in the local breast tissue and urinary tract, a recent study reveals. Particularly, species in the Methylobacterium genus are reduced in the local breast tissue while the urinary tract is enriched in gram-positive bacteria.
Pearl Toh, 13 Oct 2017
Women with higher plasma tryptophan concentrations were less likely to have poor sleep quality during pregnancy, especially among those with anxiety symptoms, according to the GUSTO* study.